News & Updates

Show Multimedia Only
Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
16 Jan 2026 byStephen Padilla

Combination treatment with the CD20×CD3 bispecific antibody odronextamab and chemotherapy is generally safe among previously untreated diffuse large B cell lymphoma (DLBCL) patients, without new safety signals, as shown by the results from part 1 of the phase III Olympia-3 study.

Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
16 Jan 2026
Maternal asthma may raise congenital heart defect risk in offspring
Maternal asthma may raise congenital heart defect risk in offspring
15 Jan 2026 byStephen Padilla

Asthma and allergic tendency in mothers appear to elevate the risk of congenital heart defect (CHD) in their children, suggests a study, noting that nonallergic asthma also contributes to such risk.

Maternal asthma may raise congenital heart defect risk in offspring
15 Jan 2026
EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC
EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC
15 Jan 2026 byAudrey Abella

In the phase III EPIK-B5 study, adding alpelisib, an α-specific PI3K inhibitor, to fulvestrant improves progression-free survival (PFS) in men and postmenopausal women with HR+, HER2− advanced breast cancer (ABC) harbouring a PIK3CA mutation who have progressed on or after treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC
15 Jan 2026